Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Moodys
Merck
Mallinckrodt
Baxter

Last Updated: October 17, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ALIMTA

See Plans and Pricing

« Back to Dashboard

Clinical Trials for Alimta

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00022646 Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed National Cancer Institute (NCI) Phase 2 2001-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer.
NCT00022646 Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Completed Alliance for Clinical Trials in Oncology Phase 2 2001-08-01 RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving more than one drug and giving the drugs in different ways may kill more tumor cells. PURPOSE: Randomized phase II trial to compare the effectiveness of three different regimens of pemetrexed disodium plus gemcitabine in treating patients who have locally advanced or metastatic non-small cell lung cancer.
NCT00034463 ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer Completed Eli Lilly and Company Phase 1 1969-12-31 This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
NCT00034502 A Trial of ALIMTA (Pemetrexed) Plus Irinotecan in Patients Who Have Been Previously Treated For Metastatic Colorectal Cancer. Completed Eli Lilly and Company Phase 1/Phase 2 1969-12-31 This is a non-randomized study in patients who have received prior 5-FU therapy for colorectal cancer. The objective of this trial is to establish a maximum tolerated dose of ALIMTA and irinotecan given in combination as well as to assess the safety and efficacy of this combination for patients with locally advanced or metastatic colorectal cancer. ALIMTA and irinotecan will be given every 21 days.
NCT00034593 A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium Completed Eli Lilly and Company Phase 2 1969-12-31 Definition: Patients with bladder cancer will be participating in this study for the treatment of abnormal cells in the bladder that have returned after initial treatment OR have moved to a new site in the body.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Alimta

Condition Name

Condition Name for Alimta
Intervention Trials
Non-small Cell Lung Cancer 25
Lung Cancer 17
Non Small Cell Lung Cancer 12
Carcinoma, Non-small-cell Lung 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Alimta
Intervention Trials
Carcinoma, Non-Small-Cell Lung 83
Lung Neoplasms 79
Mesothelioma 13
Breast Neoplasms 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Alimta

Trials by Country

Trials by Country for Alimta
Location Trials
United States 523
China 35
Italy 28
United Kingdom 25
Germany 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Alimta
Location Trials
Texas 32
Pennsylvania 32
California 28
New York 28
Ohio 24
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Alimta

Clinical Trial Phase

Clinical Trial Phase for Alimta
Clinical Trial Phase Trials
Phase 4 4
Phase 3 23
Phase 2 101
[disabled in preview] 45
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Alimta
Clinical Trial Phase Trials
Completed 105
Terminated 20
Recruiting 15
[disabled in preview] 21
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Alimta

Sponsor Name

Sponsor Name for Alimta
Sponsor Trials
Eli Lilly and Company 82
National Cancer Institute (NCI) 23
Gynecologic Oncology Group 8
[disabled in preview] 10
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Alimta
Sponsor Trials
Industry 126
Other 113
NIH 23
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Medtronic
Merck
Colorcon
McKinsey
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.